Search Results

You are looking at 191 - 200 of 865 items for :

  • Refine by Access: All x
Clear All
Full access

Testicular Cancer, Version 2.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

seminomas, because elevated marker levels are the early signs of relapse. LDH is a less-specific marker compared with AFP and hCG. AFP is a serum tumor marker produced by nonseminomatous cells (ie, embryonal carcinoma, yolk sac tumor) and may be seen at

Full access

Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar, and Dorothy A. Shead

event-free survival for CHOP-R was 36 months, whereas it was not yet reached for bendamustine and rituximab ( P < .0001). Four relapses (18%) were identified in the bendamustine and rituximab group and 11 (58%) in the CHOP-R group. Bendamustine and

Full access

Lessons From ASH 2010: A Focus on NHL

Andrew D. Zelenetz

. 10 randomized 676 patients with relapsed or progressive FL to treatment with either bortezomib (1.6 mg/m 2 on days 1, 8, 15, 22, cycles 1–5) and rituximab (375 mg/m 2 on days 1, 8, 15, 22 of cycle 1 and day 1 of cycles 2–5) or rituximab alone on

Full access

Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

whether T stage is associated with N and/or M stage,” he said. “What I would like to know in testicular cancer is which patients with stage I disease will experience relapse on surveillance. Will patients with stage II disease experience relapse if treated

Full access

Acute Myeloid Leukemia

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

and risk of relapse. The second objective focuses on patient-specific factors, including comorbid conditions that may affect an individual's ability to tolerate chemotherapy. Both disease-specific and individual patient factors are considered in

Full access

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

longer median relapse-free survival (RFS; not reached vs 20 months; P <.0001) compared with interferon-alfa; the median follow-up was 57 months. 21 After a median follow-up of 9.3 years, estimated 5- and 10-year overall survival (OS) rates for patients

Full access

Hodgkin Lymphoma

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter, and Joachim Yahalom

revised system, response is categorized as complete response, partial response, stable disease, relapsed disease, or progressive disease. Diagnosis Fine needle aspiration alone is generally insufficient for initial diagnosis. Although it is widely

Full access

The Rapid Evolution of Novel Therapies in Multiple Myeloma

Kenneth C. Anderson

-MM response may be able to overcome the ongoing genetic Table 1. Novel FDA-Approved Agents in Myeloma and epigenetic events underlying progression and relapse of disease. Clinical and regulatory strategies have already derived clinical trials

Full access

Non-Hodgkin’s Lymphomas, Version 2.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

or t(14,18), as mentioned previously. 21 , 23 , 24 Pediatric FL without BCL2 rearrangements tend to be associated with localized disease and have an indolent course and favorable prognosis, with only rare instances of disease progression or relapse

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

considered whether EFS or OS provides a more clinically meaningful endpoint for improvement. After careful deliberation, the committee determined that avoiding relapses should take top priority for subgroups with expected EFS <75% to 80%, because (1) the